Daewoong has officially launched its K-aesthetic total solution in Indonesia, centered around its flagship botulinum toxin, Nabota, marking the full-scale entry into the local aesthetic medical market.
This launch goes beyond simple product exports; it was designed to enable Indonesian medical professionals to receive direct training from Korean experts with extensive clinical experience in combination procedures. Through this, local practitioners gained access to precise, hands-on techniques, laying the groundwork for patients in Indonesia to receive global-standard aesthetic services within their own country.
Combination procedures involve simultaneous use of different aesthetic agents such as botulinum toxin, fillers, and PDO threads. Because the treatment outcomes can vary significantly depending on the interaction between substances and the sequence of administration, it is critical to have systematic procedural training. Without sufficient clinical experience and professional education, patient safety and treatment effectiveness can be compromised.
◆ From Toxin to Fillers and PDO threads: Expanded Treatment Options Enhance Both Precision and Safety for Medical Practitioners
On July 19, Daewoong Pharmaceutical and CGBIO held the “CGBIO Launching Symposium – MOVE TO NEW GEN” at the Langham Hotel in Jakarta, officially introducing five key aesthetic products—NABOTA, DCLASSY HA, DCLASSY CaHA, LUXX, and DOOTH—to the Indonesian market.
The NABOTA already exported to over 80 countries including the U.S., Canada, Brazil, and Thailand, the product is trusted by medical professionals and patients for its precision and fast onset.
DCLASSY, scheduled to launch in the second half of 2025, is a premium aesthetic brand developed using Daewoong’s proprietary technology. Its two core lineups—HA fillers and CaHA-based products—are designed for advanced treatment precision. The HA fillers come in three types (Soft, Intense, Volume) with optimized viscoelastic properties, while the patented spherical CaHA structure induces sustained collagen production for natural elasticity enhancement.
In response to growing demand for regenerative, minimally invasive, and non-invasive aesthetic treatments in Indonesia, Daewoong also plans to launch LUXX and DOOTH, PDO threads in 2025. LUXX features a high-elasticity, high-tensile structure that securely anchors sagging skin, while DOOTH uses patented T-shaped barbs for prolonged fixation and comfortable, natural-looking results.
Providing a comprehensive aesthetic solution encompassing botulinum toxin, fillers, and PDO threads enables physicians to tailor treatment combinations based on the patient’s skin condition, target area, and goals—enhancing both precision and safety.
◆ Beyond Product Launch introduction: Sharing NABOlift-Based Facial Combination Procedure Techniques
The symposium was designed to enhance understanding of practical techniques and product use tailored to real clinical environments. Approximately 100 dermatologists and aesthetic physicians from Indonesia attended, gaining insights into combination treatment procedures grounded in real clinical cases. The event was recognized for laying a solid foundation for precise and satisfactory medical aesthetic services in the local market.
Because combination procedures require consideration of interaction among botulinum toxin, fillers, and PDO threads, along with the treatment order, procedural outcomes can vary significantly. This underscores the importance of hands-on experience and systematic education for ensuring both safety and efficacy. Daewoong, as a company with deep expertise in aesthetic protocols, aims to lead the market by offering both products and integrated procedural training.
The four-session event included a keynote by Dr. Choon Shik (Yemiwon Dermatology Clinic), who introduced “NABOlift,” a representative facial treatment technique using Nabota. NABOlift, a differentiated protocol developed by Daewoong, involves injecting botulinum toxin into both the dermal and muscular layers to achieve comprehensive aesthetic effects such as facial contour lifting, wrinkle reduction, improved skin texture, facial contouring, and lifting.
Dr. Yoon noted, “Nabota is a high-purity, high-quality product with proven stability, which reduces immunogenicity and delivers consistent outcomes, making it a trusted choice in real-world clinical settings.”
dr. Inneke Jane Hidajat, MSc, FINSDV of Youth & Beauty Clinic added, “After using Nabota for glabellar lines, I observed fast and natural-looking results, which gave me confidence in its applicability for Indonesian patients. That’s why I chose to share my experience.”
The symposium also featured case studies using Daewoong’s filler products. Dr. Judy Hongjin Joo (Glassy Skin Clinic), known for sharing various K-aesthetic procedures through YouTube, introduced a neck rejuvenation technique using DCLASSY CaHA. “DCLASSY CaHA is a biostimulatory filler that induces collagen production, making it highly effective for long-term improvement in skin elasticity,” he said. “It was meaningful to share know-how that aligns well with aesthetic trends in Indonesia.”
Dr. Erivan Montilla (Dorsia Clinic) shared a procedure combining DCLASSY HA and DCLASSY CaHA, stating, “DCLASSY HA enables delicate procedures thanks to its uniform particle size and smooth injectability, while CaHA delivers lasting elasticity—making them a highly synergistic combination.”
◆ KIIMOT launch and ‘DEEP’ program to advance K-aesthetic strategy with physician-focused training
Daewoong is positioning itself as a leading company in Indonesia for total aesthetic solutions centered on combination procedures. The symposium was organized by KIIMOT (Korea-Indonesia Integrated Marketing Operation Taskforce), a joint task force launched by Daewoong and DNC Aesthetics. KIIMOT focuses on cultivating an environment where procedural techniques and products grow together by providing systematic training to local physicians based on Daewoong’s know-how in combination procedures. The DEEP (Daewoong·DNC Medical-AEsthetic Expert Program), Daewoong’s signature aesthetic training platform, will be used to strengthen combination procedure education programs in both Korea and Indonesia.
Changwoo Ha, Head of KIIMOT, emphasized, “Our goal is to ensure Indonesian patients can receive advanced and safe combination procedures without needing to travel abroad. Through practical education programs and skill dissemination, we aim to grow the local market hand-in-hand with Indonesian physicians.”
Over the past 20 years, Daewoong has led shared growth efforts in Indonesia through biopharmaceutical manufacturing, stem cell production, and scholarship programs—fostering local talent and production capacity. Recently expanding into aesthetics, Daewoong is now providing K-aesthetic services through ‘NULOOK,’ a training-centered clinic in Bali led by physicians. This long-term investment and training infrastructure marks Daewoong’s full-scale commitment to offering customized solutions and global-standard procedures to the Indonesian market.